Dave you state the obvious - of which most eyes ar
Post# of 30025
Posted On: 08/29/2014 9:35:26 PM
Re: Daveludlow #4993
Dave you state the obvious - of which most eyes are clearly fixated on - all with good cause:
IMHO, LymPro alone is worth a FMV of $350-Mil. to $500-Mil. in its current state of development = $0.48 to $0.68 pps, with 730-Mil. OS shares.
My direction is with alternatives - not so well exposed:
1.) IND for MANF RP or Wolframs DB-1
2.) final GMP Manufacturer for MANF revealed
3.) Novartis behind the scenes work on MANF DB-2 - huge JV potential
4.) PhenoGuard - partnering business model disclosure - J&J as favored choice
5.) new neurotrophic factor discovery
6.) additional undisclosed initiatives on MANF
Coupled with anticipated LymPro and Eltroprazene news - any/all of the above have the ability to move the pps to unchartered share price territory...
All the Best, JP
Quote:
3 LymPro catalysts:
1) Revenue Guidance
2) Data
3) Partnership
IMHO, LymPro alone is worth a FMV of $350-Mil. to $500-Mil. in its current state of development = $0.48 to $0.68 pps, with 730-Mil. OS shares.
My direction is with alternatives - not so well exposed:
1.) IND for MANF RP or Wolframs DB-1
2.) final GMP Manufacturer for MANF revealed
3.) Novartis behind the scenes work on MANF DB-2 - huge JV potential
4.) PhenoGuard - partnering business model disclosure - J&J as favored choice
5.) new neurotrophic factor discovery
6.) additional undisclosed initiatives on MANF
Coupled with anticipated LymPro and Eltroprazene news - any/all of the above have the ability to move the pps to unchartered share price territory...
All the Best, JP
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼